Featured Research

from universities, journals, and other organizations

New made-in-Canada therapy for bladder cancer shows promising results

Date:
May 24, 2011
Source:
Queen's University
Summary:
Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

Related Articles


"I am optimistic about the results of the trial," says Dr. Morales, professor emeritus in the Department of Urology at Queen's University and director of the Queen's University Centre for Applied Urological Research. "Positive results in the next phase of trials will move us very close to a far more effective bladder cancer treatment."

Initial human trials found that Urocidin is effective and much safer than previous treatment options for cases of superficial bladder cancer that is not responsive to Bacillus Calmette-Guιrin (BCG) therapy. A recent large North American clinical trial confirmed the initial findings, with 25 per cent of patients becoming disease-free after one year of therapy with the new drug. Patients also tolerated Urocidin well.

Dr. Morales spearheaded BCG as a bladder cancer treatment in the 1970s in collaboration with the Cancer Research Institute of New York. BCG provoked an immune response strong enough to eliminate some bladder cancers without chemicals. It was also the first effective agent approved by the FDA against solid tumors. BCG remains the first choice to treat superficial bladder cancer due to its superior efficacy over chemotherapy drugs; however, as a live bacterium, it has the potential for serious adverse effects.

"There has been a lot of concern about the adverse effects of BCG," explains Dr. Morales. "I've always thought that we should look for something better. Urocidin could be what we're looking for." Until the discovery of BCG as a bladder cancer therapy, the only alternative short of bladder removal was to put chemicals into the bladder.

Urocidin was developed by Bioniche Life Sciences Inc. A second Phase III clinical trial is underway, funded by Bioniche's licensing partner, Endo Pharmaceuticals.


Story Source:

The above story is based on materials provided by Queen's University. Note: Materials may be edited for content and length.


Cite This Page:

Queen's University. "New made-in-Canada therapy for bladder cancer shows promising results." ScienceDaily. ScienceDaily, 24 May 2011. <www.sciencedaily.com/releases/2011/05/110524162129.htm>.
Queen's University. (2011, May 24). New made-in-Canada therapy for bladder cancer shows promising results. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2011/05/110524162129.htm
Queen's University. "New made-in-Canada therapy for bladder cancer shows promising results." ScienceDaily. www.sciencedaily.com/releases/2011/05/110524162129.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) — Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) — AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) — A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins